An item in the April 30, 2001, issue of BioWorld Today should have said Sanofi-Synthelabo, of Paris, and NV Organon, of Oss, the Netherlands, were granted priority review status by the FDA for their synthetic pentasaccharide, Arixtra (fondaparinux sodium), for prevention of venous thrombo-embolic events following orthopedic surgery.

Editor¿s Note: The correction will be made in BioWorld Online.

No Comments